Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Big Three PBMs

Executive Summary

The Big Three PBMs

<table bordercolor="#808080" cellspacing="1" cellpadding="7" width="100%" border="1"> <tbody> <tr> <td valign="top" colspan="4"> <br /> <br /> <p> <font face="Times" size="5"><b>The Big Three PBMs</b></font> </p> </td> </tr> <tr> <td valign="top" colspan="4"> <p> <b><i><font face="Times" size="2">The following chart compares recent prescription and revenue figures for the combined Caremark/AdvancePCS to Medco and Express Scripts. Caremark numbers are for the 12 months through June 30; numbers for Medco and Express Scripts are for 2002.</font></i></b> </p> </td> </tr> <tr> <td valign="top" width="27%" bgcolor="#ffffff"> </td> <td valign="top" width="23%" bgcolor="#ffffff"> <p> <b><font face="Helvetica Condensed" size="2">Caremark</font></b> </p> </td> <td valign="top" width="21%" bgcolor="#ffffff"> <p> <b><font face="Helvetica Condensed" size="2">Medco</font></b> </p> </td> <td valign="top" width="29%" bgcolor="#ffffff"> <p> <b><font face="Helvetica Condensed" size="2">Express Scripts</font></b> </p> </td> </tr> <tr> <td valign="top" width="27%"> <p> <b><font face="Helvetica Condensed" size="2">Total Rx</font></b> </p> </td> <td valign="top" width="23%"> <p> <font face="Helvetica Condensed" size="2">611 mil.</font> </p> </td> <td valign="top" width="21%"> <p> <font face="Helvetica Condensed" size="2">548 mil.</font> </p> </td> <td valign="top" width="29%"> <p> <font face="Helvetica Condensed" size="2">382 mil.</font> </p> </td> </tr> <tr> <td valign="top" width="27%"> <p> <b><font face="Helvetica Condensed" size="2">Mail Rx</font></b> </p> </td> <td valign="top" width="23%"> <p> <font face="Helvetica Condensed" size="2">38 mil.</font> </p> </td> <td valign="top" width="21%"> <p> <font face="Helvetica Condensed" size="2">82 mil.</font> </p> </td> <td valign="top" width="29%"> <p> <font face="Helvetica Condensed" size="2">27 mil.</font> </p> </td> </tr> <tr> <td valign="top" width="27%"> <p> <b><font face="Helvetica Condensed" size="2">Retail Rx</font></b> </p> </td> <td valign="top" width="23%"> <p> <font face="Helvetica Condensed" size="2">573 mil.</font> </p> </td> <td valign="top" width="21%"> <p> <font face="Helvetica Condensed" size="2">467 mil.</font> </p> </td> <td valign="top" width="29%"> <p> <font face="Helvetica Condensed" size="2">355 mil.</font> </p> </td> </tr> <tr> <td valign="top" width="27%"> <p> <b><font face="Helvetica Condensed" size="2">Net Revenue</font></b> </p> </td> <td valign="top" width="23%"> <p> <font face="Helvetica Condensed" size="2">$23 bil.</font> </p> </td> <td valign="top" width="21%"> <p> <font face="Helvetica Condensed" size="2">$33 bil.</font> </p> </td> <td valign="top" width="29%"> <p> <font face="Helvetica Condensed" size="2">$12 bil.</font> </p> </td> </tr> <tr> <td valign="top" width="27%"> <p> <b><font face="Helvetica Condensed" size="2">EBITDA</font></b> </p> </td> <td valign="top" width="23%"> <p> <font face="Helvetica Condensed" size="2">$876 mil.</font> </p> </td> <td valign="top" width="21%"> <p> <font face="Helvetica Condensed" size="2">$886 mil.</font> </p> </td> <td valign="top" width="29%"> <p> <font face="Helvetica Condensed" size="2">$454 mil.</font> </p> </td> </tr> </tbody> </table>

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel